Active Biotech AB Year-end report January – December 2015
Laquinimod
· In April, it was announced that the first patient was enrolled to ARPEGGIO, which is evaluating laquinimod’s potential for treatment of primary progressive multiple sclerosis (PPMS)
· In June, it was announced that the company was to focus its operations on the laquinimod projects and adjust the organization accordingly
· In June, it was announced that the Phase 3 laquinimod study CONCERTO was fully enrolled
· In October, Teva presented data concerning laquinimod for the treatment of multiple sclerosis at the ECTRIMS congress
· The high dose group in the clinical studies CONCERTO, ARPEGGIO and LEGATO has been discontinued due to cardiovascular events
· The study results from both the pivotal clinical Phase 3 study CONCERTO in relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study ARPEGGIO, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the first half of 2017
Tasquinimod
· In April, it was announced that Active Biotech and Ipsen were to discontinue development of tasquinimod for the treatment of prostate cancer
· The final results from the 10TASQ10 study were presented in September 2015 at the ECC conference and demonstrated that while the primary endpoint was reached and tasquinimod treatment resulted in a prolonged radiographic progression-free survival (rPFS), 7.0 vs. 4.4 months, the positive effect on rPFS did not translate into an improved OS
ANYARA, Paquinimod (57-57) and ISI
· Out-licensing activities are continuing
Financial summary
| MSEK | Oct – Dec | Jan. – Dec. | ||||
| 2015 | 2014 | 2015 | 2014 | |||
| Net sales | 5.0 | 2.9 | 16.3 | 10.4 | ||
| Operating loss | -28.2 | -55.6 | -177.9 | -228.5 | ||
| Loss for the period | -40.8 | -57.0 | -193.5 | -231.5 | ||
| Loss per share, before and after dilution (SEK) | -0.45 | -0.73 | -2.15 | -3.02 | ||
| Cash and cash equivalents | 103.6 | 328.5 |
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
The report is also available at www.activebiotech.com.
Active Biotech AB Year-end report January – December 2015
—
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire
HUG#1986986